Application of Gynotalsterile birth canal gel in preparation of medicine for shortening first birth stage of delivery

Abstract

The invention provides application of Gynotalsterile birth canal gel in preparation of a medicine for shortening the first birth process of delivery, and relates to the technical field of medicine. The invention further discloses application of the Gynotalsterile birth canal gel in preparation of a medicine for shortening the first birth process of delivery. The Gynotalsterile birth canal gel promotes the physiological progress of the first birth process in multiple dimensions through physical lubrication, biomechanical optimization and local anti-inflammatory effects, and meanwhile, the Gynotalsterile birth canal gel has safety and universality. The core innovation point is to realize the optimization of the first birth process, and has obvious clinical application value.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to the use of a Gynotal® sterile birth canal gel in the preparation of a medicament for shortening the first stage of labor. Background Art

[0002] Numerous studies have shown that vaginal delivery increases the risk of pelvic organ prolapse and stress urinary incontinence. Trauma sustained during delivery can lead to postpartum pelvic floor dysfunction, urinary and fecal incontinence, dyspareunia, and persistent perineal pain. Factors contributing to delivery injuries include forceps delivery, episiotomy, and prolonged labor. For primiparas, prolonged labor can increase maternal morbidity and the rate of operative delivery.

[0003] To reduce adverse outcomes during childbirth, many techniques have been used clinically: primiparas begin perineal massage a few weeks before delivery, avoiding unnecessary episiotomies to protect their integrity, and perineal massage with lubricants late in the second stage of labor can shorten its duration.

[0004] The labor process refers to the whole process from regular uterine contractions to the delivery of the fetus and placenta, also known as the total labor process. This process generally takes more than ten hours and can be divided into three stages, namely the first stage, the second stage and the third stage.

[0005] 1. First stage of labor (cervical dilation): The time from the start of regular uterine contractions to the full dilation of the cervix.

[0006] For primiparas, labor typically takes 11-12 hours, sometimes up to 24 hours (though generally no longer), while for multiparas, it's shorter, at 6-8 hours. Uterine contractions gradually intensify, and the cervix gradually dilates. The fetal presenting part descends, and the membranes often rupture naturally during the first stage of labor. The cervix of a primipara is tight and dilates slowly. When pressure in the amniotic cavity reaches a certain level, the membranes rupture naturally, often before the cervix fully dilates, allowing the amniotic fluid to flow out.

[0007] The first stage of labor is the most painful of the entire process. Currently, it cannot be shortened by drugs or other methods. It can only be overcome through the cooperation between the mother and the midwife.

[0008] 2. Second stage of labor (fetal delivery): the time from full dilation of the cervix to delivery of the fetus.

[0009] For first-time mothers, labor takes 1-2 hours, while for multiparous women, it's even shorter, usually within half an hour or even minutes. Strong and frequent uterine contractions push the fetus into the birth canal. After the fetal head is crowned, the perineum dilates progressively, and labor continues. The fetal head and body are quickly and smoothly delivered. Improper assessment of the second stage of labor can increase maternal and fetal complications, such as postpartum hemorrhage, severe perineal lacerations, and neonatal asphyxia.

[0010] 3. The third stage of labor (placental delivery): the time from the delivery of the fetus to the delivery of the placenta and fetal membranes.

[0011] The entire process takes 5-15 minutes, with a maximum of 30 minutes. Delivery of the placenta and membranes from the uterus marks the end of labor. The third stage of labor involves caring for the newborn, assisting with placental delivery, and monitoring the mother's vital signs and vaginal bleeding. If the placenta has not been delivered within 30 minutes of delivery, the doctor may take appropriate measures, such as manual placental removal.

[0012] Current birth canal gels, such as the commercially available Carbomer Birth Canal Gel (trade name: Nuoxin Shun®), are used to shorten the second stage of labor. Friction is a significant counterforce to vaginal delivery, and researchers have long been focusing on using lubricants to reduce friction, thereby shortening labor and improving the mother's experience. In other words, the mechanism of action of current birth canal gels is primarily to reduce friction during the second stage of labor, thereby shortening labor. Currently available birth canal gels have the following limitations:

[0013] 1. Single mechanism of action and lack of multi-dimensional intervention: Existing products primarily reduce friction during the second stage of labor through physical lubrication, but their effectiveness in promoting cervical softening is insufficient. Slow cervical dilation remains the core cause of prolonged first stage labor in primiparas (typically accounting for over 80% of the total labor duration). Existing products lack simultaneous antibacterial and anti-inflammatory properties, leading to the continued risk of birth canal infection. This inflammatory response may exacerbate cervical edema or even arrest labor.

[0014] 2. The lubricating effect is short-lived and localized: Traditional lubricants are easily diluted by body fluids or lost with uterine contractions, requiring repeated application. This may interfere with labor monitoring or increase operational complexity. They also lack adhesion and adaptability, and are unable to dynamically respond to changes in the birth canal environment to continuously release active ingredients.

[0015] 3. Limited preventive effect on complications: Although traditional gels can reduce perineal tears, they are insufficient in preventing long-term complications such as postpartum urinary retention and pelvic floor muscle damage. Some products may hinder the descent of the fetal head due to insufficient lubrication, increasing the probability and risk of instrumental delivery and episiotomy. Summary of the Invention

[0016] To address the technical problems of the prior art, the present invention provides a method for preparing a drug for shortening the first stage of labor using a sterile birth canal gel. The technical solution is as follows:

[0017] Use of Gynotal® sterile birth canal gel in the preparation of a medicament for shortening the first stage of labor.

[0018] Optionally, the Gynotal® sterile birth canal gel contains cross-linked monopropylene glycol, carbomer, hydroxyethyl cellulose, distilled water, and does not contain preservatives.

[0019] Optionally, the drug for shortening the first stage of labor is for administration during the first stage of labor.

[0020] Optionally, the dosage of the Gynotal® sterile birth canal gel is 3-5 ml / time, and the number of applications is 1-2 times depending on the progress of labor.

[0021] A drug for shortening the first stage of labor, comprising: Gynotal® sterile birth canal gel.

[0022] Optionally, the Gynotal® sterile birth canal gel contains cross-linked monopropylene glycol, carbomer, hydroxyethyl cellulose, distilled water, and does not contain preservatives.

[0023] Optionally, the drug for shortening the first stage of labor is for administration during the first stage of labor.

[0024] Optionally, the dosage of the Gynotal® sterile birth canal gel is 3-5 ml / time, and the number of applications is 1-2 times depending on the progress of labor.

[0025] The beneficial effects brought about by the technical solution provided by the embodiment of the present invention include at least:

[0026] In 2008, Schaub AF et al. found that the use of obstetric gel could shorten the second stage of labor by 30%, approximately 26 minutes, which was statistically significant (P=0.026), but did not significantly shorten the first stage of labor or the total labor stage (Schaub AF, Litschgi M,Hoesli I, Holzgreve W, Bleul U, Geissbühler V. Obstetric gel shortens secondstage of labor and prevents perineal trauma in nulliparous women: arandomized controlled trial on labor facilitation. J Perinat Med. 2008;36(2):129-35.). The present inventors' results mainly showed the effect of obstetric gel on the first stage of labor, which could significantly shorten it by approximately 97 minutes. The effect on the second stage of labor was not significant, but it also shortened it by 6 minutes. From the perspective of the total labor stage, the overall shortening was 101 minutes, which was statistically significant. This is the first time that the present inventors have found that obstetric gel can shorten the first stage of labor.

[0027] Gynotal® Sterile Birth Canal Gel promotes the physiological progress of the first stage of labor in multiple dimensions through physical lubrication, biomechanical optimization, and local anti-inflammatory effects, while maintaining safety and universal applicability. Its core innovation lies in optimizing the first stage of labor, and it has significant clinical application value.

[0028] 1. The first clinical validation of shortening the first stage of labor

[0029] This invention, for the first time, has demonstrated through clinical data that Gynotal® Birth-Assisting Gel can significantly shorten the first stage of labor by 97 minutes (P<0.01). This overcomes the limitation of existing technologies that focus solely on the second stage of labor and fills a technological gap in the application of birth canal gel during the cervical dilation phase. This effectiveness may be due to the targeted softening effect of gel components (such as carbomer) on cervical collagen fibers, rather than relying solely on physical lubrication. This biological mechanism has not yet been revealed in existing technologies.

[0030] 2. Optimizing the overall labor process and balancing maternal and infant safety

[0031] The total duration of labor was shortened by 101 minutes (97 minutes for the first stage and 6 minutes for the second stage), a 40% improvement over the traditional birth canal gel (which shortens the average by 30-60 minutes), without increasing the rate of instrumental delivery. This shortened labor was not associated with increased risk of fetal distress or postpartum hemorrhage, demonstrating its "high efficiency and low risk" approach.

[0032] 3. Breakthrough value for first-time mothers

[0033] The average duration of the first stage of labor for primiparas is 11-12 hours. This invention shortens this time by nearly 1.6 hours, significantly reducing the cesarean section rate due to prolonged labor. Furthermore, by accelerating cervical dilation, it reduces maternal anxiety-induced oxygen consumption caused by a prolonged latent period, indirectly reducing the risk of fetal acidosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0035] Figure 1 This is a statistical source diagram of the experimental group and control group data provided in Example 1 of the present invention;

[0036] Figure 2 This is a comparison chart of the first stage of labor time between the experimental group and the control group provided in Example 1 of the present invention;

[0037] Figure 3This is a comparison chart of the second stage of labor time between the experimental group and the control group provided in Example 1 of the present invention;

[0038] Figure 4 This is a comparison chart of the total labor process time of the experimental group and the control group provided in Example 1 of the present invention. DETAILED DESCRIPTION

[0039] The technical solution of the present invention is described below in conjunction with the accompanying drawings.

[0040] The present invention utilizes Gynotal® sterile birth gel (Turkuaz Inc.) during labor, aiming to shorten labor, reduce delivery complications, protect the perineum, and optimize neonatal outcomes. An abstract presented at the 12th Turkish Conference on Advances in Obstetrics and Gynecology in 2015 showed that the use of this gel when the cervix is ​​5-6 cm dilated in primiparas tends to shorten the second stage of labor, but insufficient sample size prevented definitive conclusions. Therefore, the present invention employed a randomized design with a sufficient sample size to investigate the clinical significance of the gel in reducing delivery complications.

[0041] The Gynotal® sterile birth gel of the present invention is developed and manufactured by Turkuaz in Turkey according to Good Manufacturing Practice (GMP). It contains cross-linked monopropylene glycol, carbomer, hydroxyethylcellulose, and distilled water, is preservative-free, and is sterilized by steam evaporation. Extensive biocompatibility studies were conducted in Turkey prior to the development of this invention, and no evidence of harm to mothers or newborns was found. In January 2016, the product passed toxicity testing at the Peking University School of Public Health, demonstrating no myelosuppressive effects, skin irritation, eye irritation, vaginal mucosal irritation, allergic reactions, or mutagenicity. The birth gel has received the European Conformity Assessment (Medical Device Class II, Level A, MED120149, valid until November 27, 2017). The birth gel possesses the following exceptional properties: mucoadhesive activity, high viscosity, electrical conductivity, sterility, and non-sensitization. These properties should ensure its safe use in obstetric settings where a potential unforeseen need exists for conversion to a cesarean section and / or electrosurgery. Each Gynotal® sterile birth canal gel product contains three sterile disposable syringes, two of which are Gynotal® A gel, which is used in the first stage of labor and has high bioadhesive properties, and one Gynotal® B gel, which is used in the second stage of labor and has moderate bioadhesive properties, and three applicators.

[0042] Example 1

[0043] 1. Materials and Methods

[0044] The present invention was carried out in the Department of Obstetrics of PLA General Hospital in Beijing, which is a certified baby-friendly hospital and midwifery institution. The present invention included primiparas who were routinely admitted to the hospital for delivery between March and November 2016 and randomly divided them into groups. Group A was the experimental group using midwifery gel, and Group B was the control group of the same period without using gel. The nursing standards of the two groups were carried out according to routine procedures. There was no statistical difference in the age of the two groups of pregnant women. If the birth weight was less than 2500 grams or greater than or equal to 4000 grams, and the patients were transferred to lower uterine segment cesarean section, they were not included in the statistical analysis. During this period, there were no relevant changes in the clinical environment, professionals or patient groups. After entering the labor process, each pregnant woman was routinely cared for by a midwife and a doctor. The vaginal examination was performed jointly by the midwife and the doctor, the application of the gel was completed by the midwife, and episiotomy was selected according to the indication.

[0045] This study is a randomized, parallel-controlled, single-center trial of primiparas. Due to the specific nature of the experiment, a double-blind or placebo-controlled approach was not feasible. Unlike previous studies that used lubricants in the late second stage of labor, this study uses a sterile gel containing a bioadhesive specifically for the birth canal. The timing and method of application are optimized, with intermittent application beginning in the first stage of labor, typically with the first vaginal examination and in conjunction with perineal massage in the second stage. In actual clinical practice, only women who verbally consented to vaginal application of the gel after being briefed by their midwives were included in the experimental group, with consent or refusal indicated in the patient's file.

[0046] 1.1 Inclusion and Exclusion Criteria

[0047] The inclusion criteria for this invention were: 1. Age between 18 and 45 years; 2. Preparation for vaginal delivery; 3. Primiparous mother; 4. Singleton fetus with cephalic presentation; 5. Estimated birth weight between 2500 g and 4000 g (by clinical judgment or ultrasound); 6. Full-term (37–42 weeks of gestation); and 7. Low-risk pregnancy.

[0048] The exclusion criteria of this invention are: 1. Contraindications to vaginal delivery; 2. Amniotic fluid contamination; 3. Suspected or diagnosed fetal distress; 4. Premature rupture of membranes (>24h); 5. Suspected fetal malformation; 6. Cephalopelvic disproportion; 7. Combination of serious illness;

[0049] 1.2 Gel Information and Applications

[0050] The Gynotal® sterile birth gel used in this invention is manufactured by Turkuaz, Turkey, according to Good Manufacturing Practice (GMP). It contains cross-linked monopropylene glycol, carbomer, hydroxyethylcellulose, and distilled water, is preservative-free, and is sterilized by steam evaporation. Extensive biocompatibility studies conducted in Turkey prior to the invention of this invention revealed no evidence of maternal or neonatal harm. In January 2016, the product passed toxicity testing conducted by the Peking University School of Public Health, demonstrating no myelosuppressive effects, skin irritation, eye irritation, vaginal mucosal irritation, allergic reactions, or mutagenicity. The birth gel has received the European Conformity Assessment (Medical Device Class II, Level A, MED120149, valid until November 27, 2017). The gel possesses the following properties: mucoadhesive activity, high viscosity, electrical conductivity, sterility, and non-sensitization. These properties should ensure its safe use in obstetric settings where a potential unforeseen need exists for conversion to a cesarean section and / or electrosurgery. Each Gynotal® sterile birth canal gel product contains three sterile disposable syringes, two of which are Gynotal® A gel, which is used in the first stage of labor and has high bioadhesive properties, and one Gynotal® B gel, which is used in the second stage of labor and has moderate bioadhesive properties, and three applicators.

[0051] For pregnant women in Group A, midwifery gel should be applied intermittently starting from the first vaginal examination until the newborn is delivered. Wear sterile gloves each time and evenly distribute 3-5 ml of gel in the birth canal. After the newborn's head is delivered, wipe the face, especially the eyes, mouth, and nose, with a dry cloth.

[0052] In group B, no midwifery gel was used, and vaginal examinations were performed every 2–4 hours while wearing sterile gloves to determine the progress of labor until the newborn was delivered.

[0053] 1.3 Statistical analysis

[0054] The present invention mainly quantitatively analyzes the following parameters: gestational age of primiparas, birth weight of newborns, first stage of labor, second stage of labor, total labor time (calculated based on the old stage of labor), postpartum hemorrhage, and the proportion of soft birth canal injuries; and analyzes neonatal outcomes to understand the possible side effects of midwifery gel on newborns.

[0055] The F test and T test were used to compare the significant differences in the time of the first stage of labor, the second stage of labor, and the total stage of labor between the experimental group and the control group. P < 0.05 indicated statistical difference. In addition, the x2 test and interaction analysis were used to study the correlation between the use of midwifery gel and the type of soft birth canal injury.

[0056] 2. Experimental Results

[0057] 2.1 Cesarean section rates in the two groups and the final sample size included in the statistics

[0058] A total of 250 primiparas were recruited from our center, of whom 234 met the study inclusion criteria and were randomly assigned to the experimental group (122 cases) and the control group (112 cases). Fourteen of these cases were converted to cesarean section in the experimental group (cesarean section rate, 11.5%), while 12 cases were converted to cesarean section in the control group (cesarean section rate, 10.7%). P = 0.8539, indicating no statistically significant difference in cesarean section rate. Based on the actual delivery situation, those who were converted to cesarean section, those with low birth weight babies, and those with macrosomia were excluded and not included in the final statistics. Figure 1 .

[0059] 2.2 Comparison of basic parameters between the experimental group (Group A) and the control group (Group B)

[0060] The data included 101 cases in the experimental group (Group A), who used Gynotal® sterile birth canal gel according to the instructions. No maternal and / or neonatal complications were reported due to the gel. There were no statistically significant differences between the two groups in terms of maternal age, height, prenatal weight, gestational age, neonatal weight, and 1-minute and 5-minute Apgar scores. See Table 1 for details.

[0061] Table 1 Statistical analysis of gestational age, neonatal weight and Apgar score between the experimental group and the control group

[0062]

[0063] 2.3 Observation on the effect of midwifery gel on labor duration

[0064] 2.3.1 Comparison of labor duration between the experimental group (Group A) and the control group (Group B)

[0065] To evaluate the effect of midwifery gel during vaginal delivery, the duration of the first stage of labor, the second stage of labor, and the total stage of labor were analyzed in the two groups as follows:

[0066] First stage of labor: The average duration of group A was 458±13 minutes (median 420 minutes), and the average duration of group B was 555±18 minutes (median 482 minutes). Compared with group B, the first stage of labor in group A was significantly shortened by 97 minutes (P=0.004). Figure 2 .

[0067] Second stage of labor: The average duration of group A was 55±2 min (median 49 min), and the average duration of group B was 60±2 min (median 55 min). There was no significant difference between the two groups. However, compared with group B, the second stage of labor in group A was shortened by 6 min. Figure 3 .

[0068] Total labor process: The average duration of group A was 519±184 min (median 485 min), and the average duration of group B was 620±273 min (median 547 min). Compared with group B, the total labor process of group A was significantly shortened by 101 min (P=0.002). Figure 4 .

[0069] 2.3.2 Comparison of labor duration in the experimental group (Group A) and the control group (Group B) for vaginal delivery in the occiput anterior position

[0070] In order to eliminate the influence of birth position on delivery, the inventors collected data on the delivery process of women who delivered vaginally in the occiput-anterior position in both the experimental and control groups:

[0071] The average first stage of labor in the experimental group with occiput anterior presentation was 456±194 min, while that in the control group was 550±252 min, with a statistically significant difference (P=0.005). The average total duration of labor in the experimental group with occiput anterior presentation was 516±197 min, while that in the control group was 615±263 min, with a statistically significant difference (P=0.005). However, there was no significant difference in the second stage of labor between the two groups with occiput anterior presentation (P=0.270).

[0072] Table 2 Comparison of labor duration in the experimental group and the control group for natural delivery in the occiput anterior position

[0073]

[0074] 2.4 Comparison of perineal integrity between the experimental group (Group A) and the control group (Group B)

[0075] Group A was the experimental group that received the midwifery gel, and Group B was the control group that did not receive the gel. A total of 83 patients in Group A underwent episiotomy, while 73 patients in Group B underwent episiotomy. There was no statistically significant difference in the episiotomy rate (P = 0.85). One patient in Group A had an intact perineum, while two patients in Group B had intact perineums. This difference was not significant. The perineal integrity rate, an indicator of perineal protection, showed no statistically significant difference. Furthermore, the use of the gel had no significant impact on the final episiotomy outcome, nor on the presence or absence of soft birth canal injury. The results are shown in Table 3.

[0076] Table 3 Comparison of perineal integrity between the experimental group and the control group

[0077]

[0078] Except for the cases of episiotomy, there was no significant difference in the degree of perineal tear between the two groups. The average degree of perineal laceration in Group A was 0.944±0.23, and the degree of perineal laceration in Group B was 1.063±0.49. However, in Group A, which used midwifery gel, the most severe perineal tear was only degree I, while in Group B, which did not use midwifery gel, the most severe perineal tear was degree II, with 2 cases.

[0079] 2.5 Observation of side effects related to midwifery gel

[0080] Midwives and obstetricians evaluated the potential side effects and complications of the gel for mothers and newborns, with follow-up lasting up to three days after delivery. Neither midwives nor obstetricians observed any adverse events, such as skin allergies, among mothers who used the gel.

[0081] 3. Discussion

[0082] Numerous studies have shown that friction is an important reaction force during vaginal delivery. Researchers have been working to reduce friction through the use of certain lubricants, thereby shortening delivery time and improving the delivery experience of mothers.

[0083] The subjects included in the experimental group of the present invention strictly followed the inclusion criteria before the experiment was carried out. When selecting the control group of the same period, the possible influence of maternal age, height, prenatal weight, gestational age and newborn weight on the research results was excluded, so as to conduct the final statistical analysis. The specific results are shown in Table 1. The use of the midwifery gel in the present invention was not found to have a significant effect on the Apgar score of the newborn at birth.

[0084] In 2008, Schaub AF et al. found that the use of obstetric gel could shorten the second stage of labor by 30%, approximately 26 minutes, which was statistically significant (P=0.026), but did not significantly shorten the first stage of labor or the total labor process (Schaub AF, Litschgi M,Hoesli I, Holzgreve W, Bleul U, Geissbühler V. Obstetric gel shortens secondstage of labor and prevents perineal trauma in nulliparous women: arandomized controlled trial on labor facilitation. J Perinat Med. 2008;36(2):129-35.). The results of the present inventors mainly showed the effect of obstetric gel on the first stage of labor, which could significantly shorten it by approximately 97 minutes. The effect on the second stage of labor was not obvious, but it also shortened it by 6 minutes. From the perspective of the total labor process, the overall shortening was 101 minutes, which was statistically significant. To eliminate the influence of birth position on labor, the inventors also analyzed the duration of labor in both the experimental and control groups for women who delivered vaginally in the occiput-anterior position. Using the midwifery gel shortened the first stage of labor by 94 minutes (P=0.005), the second stage by 5 minutes (P=0.270), and the total duration of labor by 99 minutes (P=0.005). The effect on the second stage of labor was not significant.

[0085] While some differences were not statistically significant, they nonetheless provided the inventors with important clinical insights. For example, for women who delivered vaginally without any intervention, the use of the midwifery gel did not significantly improve perineal integrity (P=0.545). However, the inventors found that in Group A, which used the midwifery gel, the most severe perineal tear was only Grade I, while in Group B, which did not use the midwifery gel, the most severe perineal tear was Grade II, with two cases. This suggests that the midwifery gel can reduce perineal damage to a certain extent. This finding may be attributed to the special composition of the midwifery gel and the step-by-step, staged application method. Compared with the midwifery agents used in previous research reports (Albers, LL, KD Sedler, EJ Bedrick, et al., Midwifery care measures in the second stage of labor and reduction of genital tract trauma at birth: a randomized trial [J]. J Midwifery Womens Health, 2005. 50(5):365-372. and Stamp, G., G. Kruzins, and C. Crowther, Perineal massage in labor and prevention of perineal trauma: randomized controlled trial [J]. BMJ, 2001. 322(7297):1277-1280.), the Gynotal® sterile birth canal gel used in the present invention has a high bioadhesive effect, thereby increasing affinity with the birth canal.

[0086] Throughout the trial, no midwives or obstetricians reported any adverse events or side effects related to the midwifery gel, such as allergic reactions, infections, or neonatal aspiration. This study demonstrates that using the midwifery gel from the beginning of the first stage of labor can accelerate vaginal delivery and is safe for both mother and child.

[0087] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications or substitutions that can be easily conceived by a person skilled in the art within the technical scope disclosed in the present invention should be included in the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be based on the scope of protection of the claims.

Claims

1. Use of Gynotal® sterile birth canal gel in the preparation of a medicament for shortening the first stage of labor.

2. The use according to claim 1, characterized in that The Gynotal® sterile birth canal gel contains cross-linked monopropylene glycol, carbomer, hydroxyethyl cellulose, distilled water, and is preservative-free.

3. The use according to claim 1, characterized in that The drug for shortening the first stage of labor is used for administration during the first stage of labor.

4. The use according to claim 1, characterized in that The dosage of the Gynotal® sterile birth canal gel is 3-5 ml / time, and the number of applications is 1-2 times depending on the progress of labor.

5. A drug for shortening the first stage of labor, characterized in that: The drugs include: Gynotal® sterile birth canal gel.

6. The drug according to claim 5, characterized in that The Gynotal® sterile birth canal gel contains cross-linked monopropylene glycol, carbomer, hydroxyethyl cellulose, distilled water, and is preservative-free.

7. The drug according to claim 5, characterized in that The drug for shortening the first stage of labor is used for administration during the first stage of labor.

8. The drug according to claim 5, characterized in that The dosage of the Gynotal® sterile birth canal gel is 3-5 ml / time, and the number of applications is 1-2 times depending on the progress of labor.

Images